National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Tafamidis (Vyndaqel®). HTA ID: 20017

Tafamidis (Vyndaqel®) is indicated for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy.

 

NCPE Assessment Process Complete
Rapid review commissioned 30/03/2020
Rapid review completed 07/04/2020
Rapid Review outcome A full HTA is recommended to assess the clinical and cost effectiveness of tafamidis compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 29/04/2020
Pre-submission consultation with Applicant 18/05/2020
Full submission received from Applicant 01/07/2020
Preliminary review sent to Applicant 18/08/2020
NCPE assessment recommenced 10/09/2020
Factual accuracy sent to Applicant 11/09/2020
NCPE assessment recommenced 18/09/2020
NCPE assessment completed 25/09/2020
NCPE assessment outcome The NCPE recommends that tafamidis not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.